Large unmet clinical needs are driving demand for better transseptal access to the left heart
The rapid development of transcatheter therapies for atrial fibrillation and heart disease has seen a shift in the importance of transseptal puncture as a route to the left heart.
These clinical needs have strong procedural growth and are driving a ~$2B transseptal access market opportunity
- Aging population
- Growing prevalence of heart disease
- Global healthcare access
- Increasing diagnostic access
- Innovations in Interventional Cardiology & Electrophysiology (TEER, TMVR, TMVr, LAAC, Cryo, PFA)